Hematopoietic and Lymphoid Cell Neoplasm Clinical Trial
Official title:
ECHO Telementoring to Improve Quality Palliative Care in Underserved Areas of Kenya, Nigeria, Ghana, South Africa, India, and Ethiopia
This trial investigates the experience and satisfaction of care in patients with cancer that has spread to other places in the body (advanced) and their caregivers living in underserved areas of Kenya, Nigeria, Ghana, South Africa, India and Ethiopia as part of Project Extension for Community Healthcare Outcomes (ECHO). Project ECHO is a model of medical education and care management that empowers clinicians to provide better care to more people where they live. Understanding the experiences and satisfaction of patients and caregivers may help improve healthcare workforce capacity and increase access to specialty care for the world's rural and underserved populations.
| Status | Recruiting |
| Enrollment | 312 |
| Est. completion date | December 31, 2026 |
| Est. primary completion date | December 31, 2026 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | All |
| Age group | N/A and older |
| Eligibility | Inclusion Criteria: - PATIENT: Scheduled to receive treatment at participating primary care practice for advanced cancer - PATIENT: 18 years or older - PATIENT: Willing to be accessible to the research team for follow-up by telephone or in person - PATIENT: Prognosis of at least 1 year as ascertained by the treating physician - PATIENT: Able to read and understand English as assessed by the treating physician - CAREGIVER: Identified or self-identified as primary caregiver of the patient - CAREGIVER: Willing to be accessible to the research team for follow-up by telephone or in person - CAREGIVER: 18 years or older - CAREGIVER: Able to read and understand English as assessed by the treating physician - ECHO PARTICIPANT: Participant must be a health care provider interested to participate in the study for 2 years and understand the protocol and provide consent - ECHO PARTICIPANT: Able to read and understand English as assessed by principal investigator (PI) Exclusion Criteria: - Unable to understand and sign consent |
| Country | Name | City | State |
|---|---|---|---|
| United States | M D Anderson Cancer Center | Houston | Texas |
| Lead Sponsor | Collaborator |
|---|---|
| M.D. Anderson Cancer Center | National Cancer Institute (NCI) |
United States,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Change in patients' quality of life | Measured by Functional Assessment of Cancer Illness Therapy FACT-General (FACT-G). A 27-item compilation of general questions divided into four primary domains: Physical Well-Being, Social/Family Well-Being, Emotional Well-Being, and Functional Well-Being. Each question is assessed using a Likert scale ranging from 0 to 4. The FACT-G total score is the sum of the domain scores.. | Baseline up to 12 months | |
| Secondary | Change in patients' symptom distress | Will be assessed by the Edmonton Symptom Assessment Scale, Symptom Distress Scores, (ESAS-SDS). The ESAS is a validated questionnaire measuring 10 symptoms (pain, fatigue, nausea, depression, anxiety, drowsiness, shortness of breath, appetite, sleep, and well-being). It has good reliability and can be completed within minutes. The ESAS-SDS will be calculated by the sum of the symptom scores of measures ESAS Pain, ESAS Fatigue, ESAS nausea, ESAS Depression, ESAS anxiety, ESAS drowsiness, ESAS Dyspnea, ESAS Appetite, ESAS Well-being. | Baseline up to 2 years | |
| Secondary | Patients' satisfaction of care | Assessed by FAMCARE P16, a self-report scale assessing patient experience and satisfaction with outpatient palliative oncology care, which is composed of 16 items rated from 1 (very dissatisfied) to 5 (very satisfied). The items are not specific for a particular tumor type or symptom but are broadly relevant for outpatients with advanced cancer; the summed items produce a single satisfaction score. | Baseline up to 2 years. | |
| Secondary | Caregivers' satisfaction of care | Assessed by FAMCARE -cg scale, which measures the degree of experience and satisfaction of the caregivers with health care in terms of information provided, availability of care, physical individual with advanced cancer care, and psychological care for patients. | Baseline up to 2 years | |
| Secondary | Providers' efficacy in knowledge of delivering palliative care | Assessed by completing the Palliative Care Participant Initial Survey | Baseline | |
| Secondary | Providers' efficacy in knowledge of delivering palliative care | Assessed by completing the Palliative Care Participant Follow up Survey composed of 9 questions about providers' knowledge of assessments performed in the palliative care setting. | Up to 2 years | |
| Secondary | Providers' competence to deliver palliative care | Measured by the distance technology sessions held twice monthly. | Baseline up to 2 years | |
| Secondary | Providers' Satisfaction and feedback | Assessed by completing 7 questions about providers' opinions of distance learning technology. | Baseline up to 2 years | |
| Secondary | Burnout among ECHO participant | Measured by Maslach Burnout Inventory-Human Services Survey (MBI-HSS). It consists of three factors (depersonalization [DP], emotional exhaustion [EE], and personal achievement [PA]) with 22 items, each scored on a 7-point Likert scale. DP and EE scores are positively correlated with burnout, while PA is negatively correlated. | Baseline up to 2 years |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04337203 -
Shared Healthcare Actions and Reflections Electronic Systems in Survivorship
|
N/A | |
| Recruiting |
NCT05106374 -
Risk of Chemotherapy Toxicity in Older Patients With Blood Cancer or Non-small Cell Lung Cancer
|
||
| Recruiting |
NCT05660421 -
Itacitinib for the Treatment Steroid Refractory Immune Related Adverse Events Arising From Immune Checkpoint Inhibitors
|
Phase 2 | |
| Suspended |
NCT04060849 -
Nozin in Preventing Respiratory Viral Infections in Patients Undergoing Stem Cell Transplant, PREV-NOSE STUDY
|
Phase 1 | |
| Completed |
NCT04666025 -
SARS-CoV-2 Donor-Recipient Immunity Transfer
|
||
| Withdrawn |
NCT04127721 -
Itacitinib for the Prevention of Graft Versus Host Disease in Patients Undergoing Donor Stem Cell Transplantation
|
Phase 2 | |
| Active, not recruiting |
NCT03712878 -
2-Step Approach to Stem Cell Transplant in Treating Participants With Hematological Malignancies
|
Phase 2 | |
| Active, not recruiting |
NCT06062901 -
An Educational Intervention on Provider Knowledge for the Support of Cancer Survivors
|
N/A | |
| Terminated |
NCT04081298 -
eHealth Diet and Physical Activity Program for the Improvement of Health in Rural Latino Cancer Survivors
|
N/A | |
| Completed |
NCT04983901 -
PHASE II SINGLE-CENTER, RANDOMIZED, OPEN-LABEL, PROSPECTIVE, STUDY TO DETERMINE THE IMPACT OF SERIAL PROCALCITONIN
|
Phase 2 | |
| Recruiting |
NCT04188912 -
Close Assessment and Testing for Chronic Graft Versus Host Disease, CATCH Study
|
||
| Active, not recruiting |
NCT04592250 -
Financial Toxicity in Cancer Patients
|
||
| Recruiting |
NCT05112614 -
Role of Gut Microbiome in Cancer Therapy
|
||
| Active, not recruiting |
NCT04296305 -
Effect of Opioid Infusion Rate on Abuse Liability Potential of Intravenous Hydromorphone for Cancer Pain
|
Phase 4 | |
| Withdrawn |
NCT04190433 -
Autophagy Activation for the Alleviation of Cardiomyopathy Symptoms After Anthracycline Treatment, ATACAR Trial
|
Phase 2 | |
| Terminated |
NCT04083170 -
Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic Cancers
|
Phase 2 | |
| Recruiting |
NCT02464696 -
Non-invasive Ventilation in Reducing the Need for Intubation in Patients With Cancer and Respiratory Failure
|
N/A | |
| Withdrawn |
NCT04820894 -
Perception of Cure Among Patients With Metastatic Cancer
|
||
| Completed |
NCT03125070 -
Self-Management Program and Survivorship Care Plan in Improving the Health of Cancer Survivors After Stem Cell Transplant
|
Phase 3 | |
| Completed |
NCT01664910 -
CMC-544 and Allogeneic Transplantation for CD22 Positive-Lymphoid Malignancies
|
Phase 1/Phase 2 |